Result of AGM
Solvonis Therapeutics plc announced that all resolutions were passed at its Annual General Meeting, with strong shareholder support for receiving the 2025 accounts, approving the remuneration policy and report, re-appointing auditors and directors, and authorizing the directors to allot equity and disapply pre-emption rights. The company, focused on CNS disorders, highlighted progress in its Alcohol Use Disorder programs (SVN-001 and SVN-002) and its discovery programs for PTSD, stimulant use disorder, and depression, aiming to create long-term shareholder value.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
LONDON - June 19, 2026 - Solvonis Therapeutics plc (LSE: SVNS) ("Solvonis" or the "Company"), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that at the Annual General Meeting of the Company held earlier today, all resolutions put to shareholders were duly passed.
Voting on all resolutions was conducted by way of a poll. Full details of the poll results are set out below.
Dennis Purcell, Non-Executive Chairman of Solvonis, commented: "On behalf of the Board, I would like to thank shareholders for their continued support at today's Annual General Meeting.
"The past year has been an important period in the development of Solvonis, during which the Company completed its transition into a focused CNS therapeutics business and established a broader, more coherent portfolio across addiction and psychiatry.
"We are pleased with the balanced progress being made across the portfolio, including our later-stage clinical programmes in Alcohol Use Disorder and our emerging discovery and preclinical opportunities in PTSD, stimulant use disorder and depression.
"The Board remains focused on disciplined execution, capital-efficient development and creating long-term value for shareholders. We look forward to updating the market, as appropriate, on continued progress across the portfolio through the remainder of 2026."
The Company's strategy is to build a differentiated CNS therapeutics portfolio across areas of high unmet need, with later-stage clinical assets complemented by internally generated discovery programmes. Solvonis' current portfolio includes SVN-001, its lead programme in severe Alcohol Use Disorder; SVN-002, its U.S.-focused Alcohol Use Disorder programme; and discovery and preclinical programmes including SVN-114 in PTSD and SVN-015 in stimulant use disorder and depression.
Voting Results:
| Resolution | Votes for | % Votes Cast | Votes against | % Votes Cast | Total Votes | Votes withheld |
|---|---|---|---|---|---|---|
| Resolution 1 (Ordinary) To receive the report and accounts for the year ended 31 December 2025 | 1,155,565,533 | 96.16% | 46,093,340 | 3.84% | 1,201,658,873 | 1,589,104 |
| Resolution 2 (Ordinary) To approve the remuneration policy | 1,113,689,240 | 95.46% | 52,967,133 | 4.54% | 1,166,656,373 | 36,591,604 |
| Resolution 3 (Ordinary) To approve the remuneration report | 1,113,689,240 | 95.46% | 52,967,133 | 4.54% | 1,166,656,373 | 36,591,604 |
| Resolution 4 (Ordinary) To re-appoint Kreston Reeves LLP as auditor | 1,197,595,249 | 99.53% | 5,652,728 | 0.47% | 1,203,247,977 | 0 |
| Resolution 5 (Ordinary) To re-appoint Paul Carter as a director | 1,151,080,001 | 95.66% | 52,167,976 | 4.34% | 1,203,247,977 | 0 |
| Resolution 6 (Ordinary) To re-appoint Anthony Tennyson as a director | 1,151,313,351 | 99.49% | 5,934,626 | 0.51% | 1,157,247,977 | 46,000,000 |
| Resolution 7 (Ordinary) To re-appoint Nicholas Nelson as a director | 1,151,080,001 | 95.66% | 52,167,976 | 4.34% | 1,203,247,977 | 0 |
| Resolution 8 (Ordinary) To authorise the directors to allot equity | 1,146,194,662 | 95.26% | 57,053,315 | 4.74% | 1,203,247,977 | 0 |
| Resolution 9 (Special) That a general meeting, other than an AGM, may be called on not less than 14 days' notice | 1,162,592,749 | 96.62% | 40,655,228 | 3.38% | 1,203,247,977 | 0 |
| Resolution 10 (Special) To disapply pre-emption rights | 1,026,314,705 | 94.85% | 55,700,737 | 5.15% | 1,082,015,442 | 121,232,535 |
As at 19 June 2026, there were 6,806,403,493 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for or against a resolution.
In accordance with the UK Listing Rules, copies of the resolutions passed at the Annual General Meeting concerning special business will be submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
| solvonis.com | X |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.